Explore All Access
Check if your research matches the topics covered in Lung Cancer: Targets and Therapy?
- Degree of match
- Common matching concepts
- Additional journal recommendations
Lung Cancer: Targets and Therapy : Impact Factor & More
eISSN: 1179-2728pISSN: 1179-2728
Open AccessShare this on:
Check your submission readiness
Find out how your manuscript stacks up against 24 technical compliance and 6 language quality checks.
Lung Cancer: Targets and Therapy Key Metrics
CiteScore 
6.5
SNIP
1.15
Lung Cancer: Targets and Therapy Journal Specifications
Indexed in the following public directories
Web of Science 
Scopus 
DOAJ 
SJR
| Overview | |
| Publisher | DOVE MEDICAL PRESS LTD |
| Language | English |
| Frequency | Continuous publication |
| Article Processing Charges | USD 2390 |
| Publication Time | 16 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Language | English |
| Frequency | Continuous publication |
| Publication Start Year | 2008 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY, CC BY-NC |
| OA statement | Visit website |
View less
Planning to publish in Lung Cancer: Targets and Therapy ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Lung Cancer: Targets and Therapy
Adagrasib in KRYSTAL-12has Broken the KRAS G12C Enigma Code in Non-Small Cell Lung Carcinoma.
- 1 Oct 2024
- Lung Cancer (Auckland, N.Z.)
NRG1 Fusions in NSCLC: Being eNRGy Conscious.
- 1 Oct 2024
- Lung Cancer (Auckland, N.Z.)
Real-World Outcomes with Lurbinectedin in Second Line and Beyond for Extensive Stage Small Cell Lung Cancer in Korea.
- 1 Oct 2024
- Lung Cancer (Auckland, N.Z.)
Redefining Recovery: The Transformative Impact of the ALINA Trial on Adjuvant Therapy for ALK-Positive Non-Small Cell Lung Cancer.
- 1 Aug 2024
- Lung Cancer (Auckland, N.Z.)
Mutation of MET D1228N as an Acquired Potential Mechanism of Crizotinib Resistance in NSCLC with MET Y1003H Mutation.
- 1 Aug 2024
- Lung Cancer (Auckland, N.Z.)
Spotlight on Patritumab Deruxtecan (HER3-DXd) from HERTHENA Lung01. Is a Median PFS of 5.5 Months Enough in Light of FLAURA-2 and MARIPOSA?
- 1 Jul 2024
- Lung Cancer (Auckland, N.Z.)
Adagrasib in KRYSTAL-12has Broken the KRAS G12C Enigma Code in Non-Small Cell Lung Carcinoma.
- 1 Oct 2024
- Lung Cancer (Auckland, N.Z.)
NRG1 Fusions in NSCLC: Being eNRGy Conscious.
- 1 Oct 2024
- Lung Cancer (Auckland, N.Z.)
Real-World Outcomes with Lurbinectedin in Second Line and Beyond for Extensive Stage Small Cell Lung Cancer in Korea.
- 1 Oct 2024
- Lung Cancer (Auckland, N.Z.)
Redefining Recovery: The Transformative Impact of the ALINA Trial on Adjuvant Therapy for ALK-Positive Non-Small Cell Lung Cancer.
- 1 Aug 2024
- Lung Cancer (Auckland, N.Z.)
Mutation of MET D1228N as an Acquired Potential Mechanism of Crizotinib Resistance in NSCLC with MET Y1003H Mutation.
- 1 Aug 2024
- Lung Cancer (Auckland, N.Z.)
Spotlight on Patritumab Deruxtecan (HER3-DXd) from HERTHENA Lung01. Is a Median PFS of 5.5 Months Enough in Light of FLAURA-2 and MARIPOSA?
- 1 Jul 2024
- Lung Cancer (Auckland, N.Z.)
FAQs on Lung Cancer: Targets and Therapy
How long has Lung Cancer: Targets and Therapy been actively publishing? 
Lung Cancer: Targets and Therapy has been in operation since 2008 till date.
What is the publishing frequency of Lung Cancer: Targets and Therapy?
Lung Cancer: Targets and Therapy published with a Continuous publication frequency.
How many articles did Lung Cancer: Targets and Therapy publish last year?
In 2023, Lung Cancer: Targets and Therapy publsihed 12 articles.
What is the eISSN & pISSN for Lung Cancer: Targets and Therapy?
For Lung Cancer: Targets and Therapy, eISSN is 1179-2728 and pISSN is 1179-2728.
What is Citescore for Lung Cancer: Targets and Therapy?
Citescore for Lung Cancer: Targets and Therapy is 6.5.
What is SNIP score for Lung Cancer: Targets and Therapy?
SNIP score for Lung Cancer: Targets and Therapy is 1.15.
Who is the publisher of Lung Cancer: Targets and Therapy?
DOVE MEDICAL PRESS LTD is the publisher of Lung Cancer: Targets and Therapy.
